Form D · Pharmaceuticals

Leafline Labs, LLC

Cottage Grove, MN · CIK 0001621013

Offering snapshot reported May 9, 2016 · SEC filing

Reported sold
$150K
Offering amount: $21M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 25, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 9, 2016Initial$149,600No comparison1SEC filing
Oct 30, 2015Amendment$14,948,643$2,549,443vs Dec 4, 2014141SEC filing
Dec 4, 2014Initial$12,399,200No comparison113SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-262770

Source: Form D, filed May 9, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Bachman Promoter
Peter Bachman Promoter
Andrew Bachman Director, Executive, Promoter
Mark Bachman Promoter
Mitchell Baruchowitz Director, Promoter
Kelly Henry Promoter
Colin Kelley Executive
Tara Mulloy Executive
Emmanuel Munson Regala Executive
Ethan Ruby Director, Promoter
Gary Starr Promoter
Glenn Taylor Director, Promoter
Christopher Weidling Executive, Promoter

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
8235 97th Street South
Cottage Grove, MN, 55016